Popular Targets for Bispecific Antibody Drugs Bispecific Antibody drugs have gained considerable popularity since the approval of blinatumomab. Currently, six bsAb drugs have been approved by the US FDA / EMA and over 180 are currently in clinical trials. BsAb simultaneously recognize different antigens or epitopes, resulting in a diverse range of therapeutic mechanisms. With a […]
BiTE Antibodies: A Promising Cancer Therapy About Bispecific Antibodies A bispecific antibody drug (BsMAb, BsAb) is a synthetic protein that can bind to two distinct antigen types or two distinct epitopes on the same antigen at the same time. BsAbs can be produced in a variety of structural forms and can be created to induce […]
An Introduction Bispecific Antibody Therapeutics Bispecific antibodies, as the name suggests, are antibodies with two binding sites – directed against two different antigens, or in some cases, two different epitopes on the same antigen. While mAbs have become mainstays in various therapies, they have several limitations – not including failed treatment responses and the development […]
Explore Krishgen’s blog for expert insights on ELISA assays, life science research, biotech innovations, laboratory best practices, and product updates designed to support scientists and research institutions.
